Free Trial

Bioventus (BVS) Stock Price, News & Analysis

Bioventus logo
$7.24 -0.04 (-0.48%)
Closing price 03:59 PM Eastern
Extended Trading
$7.23 -0.01 (-0.21%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Bioventus Stock (NYSE:BVS)

Key Stats

Today's Range
$7.07
$7.28
50-Day Range
$6.14
$7.64
52-Week Range
$5.81
$14.38
Volume
246,763 shs
Average Volume
395,956 shs
Market Capitalization
$599.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.75
Consensus Rating
Moderate Buy

Company Overview

Bioventus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
66th Percentile Overall Score

BVS MarketRank™: 

Bioventus scored higher than 66% of companies evaluated by MarketBeat, and ranked 365th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Bioventus has a consensus price target of $13.75, representing about 89.8% upside from its current price of $7.25.

  • Amount of Analyst Coverage

    Bioventus has only been the subject of 1 research reports in the past 90 days.

  • Read more about Bioventus' stock forecast and price target.
  • Earnings Growth

    Earnings for Bioventus are expected to grow by 12.20% in the coming year, from $0.41 to $0.46 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bioventus is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bioventus is -11.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bioventus has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for BVS.
  • Dividend Yield

    Bioventus does not currently pay a dividend.

  • Dividend Growth

    Bioventus does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for BVS.
  • News Sentiment

    Bioventus has a news sentiment score of 1.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Bioventus this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Bioventus to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bioventus insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    33.00% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Bioventus' insider trading history.
Receive BVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BVS Stock News Headlines

Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.tc pixel
Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript
Bioventus Inc. Reports Q2 2025 Financial Results
See More Headlines

BVS Stock Analysis - Frequently Asked Questions

Bioventus' stock was trading at $10.50 at the start of the year. Since then, BVS stock has decreased by 31.0% and is now trading at $7.2450.

Bioventus Inc. (NYSE:BVS) announced its quarterly earnings data on Tuesday, November, 5th. The company reported $0.06 EPS for the quarter, meeting analysts' consensus estimates of $0.06. The company earned $138.96 million during the quarter, compared to analyst estimates of $132.57 million. Bioventus had a negative net margin of 7.11% and a positive trailing twelve-month return on equity of 15.61%.

Bioventus (BVS) raised $126 million in an initial public offering on Thursday, February 11th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity served as the underwriters for the IPO.

Bioventus' top institutional shareholders include Nantahala Capital Management LLC (6.43%), American Century Companies Inc. (1.37%), Divisadero Street Capital Management LP (1.32%) and Geode Capital Management LLC (1.28%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, Mark Leonard Singleton, William A Hawkins, Anthony P Bihl III, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali.
View institutional ownership trends
.

Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/05/2024
Today
9/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NYSE:BVS
CIK
1665988
Fax
N/A
Employees
1,200
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$12.00
Potential Upside/Downside
+92.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
17.39
P/E Growth
N/A
Net Income
-$156.23 million
Net Margins
-7.11%
Pretax Margin
-10.41%
Return on Equity
15.61%
Return on Assets
4.01%

Debt

Debt-to-Equity Ratio
1.85
Current Ratio
1.41
Quick Ratio
0.99

Sales & Book Value

Annual Sales
$564.14 million
Price / Sales
1.04
Cash Flow
$0.57 per share
Price / Cash Flow
12.58
Book Value
$2.80 per share
Price / Book
2.55

Miscellaneous

Outstanding Shares
82,679,000
Free Float
54,455,000
Market Cap
$589.50 million
Optionable
Not Optionable
Beta
0.84
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSE:BVS) was last updated on 9/12/2025 by MarketBeat.com Staff
From Our Partners